Company Description

26therapeutics, an adMare BioInnovations company, is a preclinical-stage biotechnology company developing small-molecule therapies for dry eye disease and other meibomian gland disorders. The company’s lead program is a topical, disease-modifying approach designed to restore meibomian gland function.